Exclusive deal expands neurodegenerative diagnostics (opens in new tab)

NanoDetection secures global rights to antibody technology that may help distinguish Alzheimer’s from other brain diseases. A new licensing deal aims to bring greater precision to one of medicine’s biggest challenges: understanding what is happening inside the aging brain. Life science and diagnostics company NanoDetection Technology and New York-based biotech Oligomerix have announced an exclusive […] The post appeared first on <a href="